News

Filter

Current filters:

None

Popular Filters

8110 to 8134 of 8806 results

UK MHRA proposes safeguard for medicines supplies for patients

01-11-2011

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has proposed repeal of the part…

EuropeMarkets & MarketingPharmaceuticalRegulation

Drugmakers are using innovative partnerships to spur development, says Tufts CSDD

01-11-2011

Responding to strong and growing pressure to reduce development times and increase the output of new…

LicensingNorth AmericaPharmaceuticalResearch

Global bio-pharma clinical leaders to call for industry transformation at 21st Annual Partnerships in Clinical Trials

01-11-2011

Clinical development, outsourcing and operations decision makers from the world’s top bio-pharmaceutical…

BiotechnologyPharmaceuticalResearch

Pres Obama orders FDA action to reduce Rx drug shortages in USA

01-11-2011

in frequency and severity in recent years and adversely affecting patient care. A small number of drugs…

GenericsNorth AmericaPharmaceuticalPoliticsRegulation

UK NICE recommends Boehringer’s Pradaxa for stroke prevention

01-11-2011

In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

NPS Pharma posts overall positive Gattex data, but shares plunge due to two deaths

01-11-2011

Shares in USA-based NPS Pharmaceuticals (Nasdaq: NPSP) plummeted as much as 38% to $4.92 in morning trading…

Gastro-intestinalsGattexNPS PharmaceuticalsNycomedPharmaceuticalResearchRevestive

MS drugs push Biogen Idec 3rd-qtr 2011 net income 38% higher

01-11-2011

US biotech company Biogen Idec (Nasdaq: BIIB) posted third-quarter 2011 financial results, showing that…

Biogen IdecBiotechnologyFinancial

Oxford BioMedica in glaucoma R&D accord with Mayo Clinic

31-10-2011

UK-based Oxford BioMedica (LSE: OXB) has entered into an R&D collaboration with the USA’s Mayo Clinic…

BiotechnologyLicensingOphthalmicsOxford BioMedicaPharmaceuticalResearchSanofi

Expanding Norwegian cancer cluster adds new start-ups

31-10-2011

In Norway, the Oslo Cancer Cluster represents a strong R&D environment dedicated to oncology. The true…

AlgetaEuropeOncologyPharmaceuticalPhotocureResearch

Australia’s GMiA completes Code review; comments on PBS cuts and vital role of pharma manufacturing

31-10-2011

Martin Cross, chairman of Australia’s Generic Medicines Industry Association (GMiA) has warned that…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalPricingRegulation

Merck & Co posts strong 3rd-qtr 2011results as profit leaps 9.9% and sales rise 8%

31-10-2011

US drugs giant Merck & Co (NYSE: MRK) post third-quarter 2011 financial results late Friday, showing…

FinancialMerck & CoPharmaceutical

Roche offers Germany a pay-for-performance deal on Avastin

31-10-2011

In Germany’s tight market for new and existing drugs to gain reimbursement, Swiss drug major Roche…

AvastinEuropeOncologyPharmaceuticalPricingRoche

Brazil pharma market driven by generic medicines

31-10-2011

According to the Ministry of Health, the Brazilian pharmaceutical market has grown to $28 billion annually,…

GenericsMarkets & MarketingPharmaceuticalSouth America

Shire posts strong 3rd-qtr 2011 results, with sales beating expectations

31-10-2011

The UK’s third largest drugmaker, Shire (LSE: SHP), reported third-quarter 2011 total revenues of…

FinancialPharmaceuticalShire

Greece’s Pharma industry faced with most challenging environment in Europe

30-10-2011

It is now beyond doubt that drugmakers in Greece - particularly domestic producers, primarily exposed…

EuropeMarkets & MarketingPharmaceutical

Regular aspirin intake halves hereditary cancer risk, scientists conclude

30-10-2011

Scientists, including those from Queen's University in Belfast, Northern Ireland, have discovered that…

OncologyPharmaceuticalResearch

Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report

30-10-2011

By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

8110 to 8134 of 8806 results

Back to top